Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Lurasidone Pediatric Bipolar Study
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT02046369
- Locations
- 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT02024607
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Pediatric Open-Label Extension Study
- Conditions
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 702
- Registration Number
- NCT01914393
- Locations
- 🇺🇸
Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University of South Florida, Saint Petersburg, Florida, United States
Lurasidone Pediatric Autism Study
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01911442
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC, Maitland, Florida, United States
🇺🇸Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States
🇺🇸Capstone Clinical Research, Inc., Libertyville, Illinois, United States
Pediatric Schizophrenia Efficacy and Safety Study
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 327
- Registration Number
- NCT01911429
- Locations
- 🇧🇬
MHAT-Targovishte, AD, Targovishte, Bulgaria
🇨🇴Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia
🇫🇷Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France
Lurasidone Low-Dose - High-Dose Study Study
- Conditions
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT01821378
- Locations
- 🇺🇸
Center for Behavioral Health, LLC, Rockville, Maryland, United States
🇷🇴Spitalul Universitar de Urgenta Militar Central "Dr Carol Davila", Bucuresti, Romania
🇷🇴Spitalul Judetean de Urgenta "Sf. Pantelimon" Focsani, Focsani, Romania
A Study of BBI503 in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 311
- Registration Number
- NCT01781455
- Locations
- 🇺🇸
Texas Oncology- Tyler, Tyler, Texas, United States
🇺🇸Institute for Translational Oncology Research, Greenville Hospital System, Greenville, South Carolina, United States
🇺🇸Texas Oncology- Fort Worth, Fort Worth, Texas, United States
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01776307
- Locations
- 🇺🇸
USOR - Texas Oncology Tyler, Tyler, Texas, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸US Oncology Research, The Woodlands, Texas, United States
A Study of BBI608 in Adult Patients With Advanced Malignancies
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01775423
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸Institute for Translational Oncology Research, Greenville Hospital System, Greenville, South Carolina, United States
🇨🇦Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01774747
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States